Logo image of FLGT

FULGENT GENETICS INC (FLGT) Stock Fundamental Analysis

NASDAQ:FLGT - Nasdaq - US3596641098 - Common Stock - Currency: USD

20.78  +2.42 (+13.18%)

After market: 20.78 0 (0%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to FLGT. FLGT was compared to 103 industry peers in the Health Care Providers & Services industry. The financial health of FLGT is average, but there are quite some concerns on its profitability. FLGT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year FLGT was profitable.
FLGT had a negative operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: FLGT reported negative net income in multiple years.
In the past 5 years FLGT always reported a positive cash flow from operatings.
FLGT Yearly Net Income VS EBIT VS OCF VS FCFFLGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

FLGT has a worse Return On Assets (-4.25%) than 65.05% of its industry peers.
FLGT has a Return On Equity (-4.57%) which is in line with its industry peers.
Industry RankSector Rank
ROA -4.25%
ROE -4.57%
ROIC N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
FLGT Yearly ROA, ROE, ROICFLGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Gross Margin of FLGT (40.04%) is better than 67.96% of its industry peers.
In the last couple of years the Gross Margin of FLGT has declined.
The Profit Margin and Operating Margin are not available for FLGT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 40.04%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
FLGT Yearly Profit, Operating, Gross MarginsFLGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

6

2. Health

2.1 Basic Checks

FLGT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for FLGT has been increased compared to 1 year ago.
Compared to 5 years ago, FLGT has more shares outstanding
FLGT has a better debt/assets ratio than last year.
FLGT Yearly Shares OutstandingFLGT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
FLGT Yearly Total Debt VS Total AssetsFLGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

FLGT has an Altman-Z score of 5.62. This indicates that FLGT is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 5.62, FLGT belongs to the best of the industry, outperforming 84.47% of the companies in the same industry.
A Debt/Equity ratio of 0.00 indicates that FLGT is not too dependend on debt financing.
FLGT has a better Debt to Equity ratio (0.00) than 85.44% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.62
ROIC/WACCN/A
WACC8.86%
FLGT Yearly LT Debt VS Equity VS FCFFLGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 6.01 indicates that FLGT has no problem at all paying its short term obligations.
FLGT's Current ratio of 6.01 is amongst the best of the industry. FLGT outperforms 95.15% of its industry peers.
A Quick Ratio of 6.01 indicates that FLGT has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 6.01, FLGT belongs to the best of the industry, outperforming 95.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.01
Quick Ratio 6.01
FLGT Yearly Current Assets VS Current LiabilitesFLGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

FLGT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1433.33%, which is quite impressive.
The Earnings Per Share has been growing by 22.18% on average over the past years. This is a very strong growth
FLGT shows a small growth in Revenue. In the last year, the Revenue has grown by 4.30%.
FLGT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 54.21% yearly.
EPS 1Y (TTM)1433.33%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%-53.33%
Revenue 1Y (TTM)4.3%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%15.17%

3.2 Future

Based on estimates for the next years, FLGT will show a very negative growth in Earnings Per Share. The EPS will decrease by -41.03% on average per year.
FLGT is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.88% yearly.
EPS Next Y-214.49%
EPS Next 2Y-81.78%
EPS Next 3Y-41.03%
EPS Next 5YN/A
Revenue Next Year9.64%
Revenue Next 2Y10.04%
Revenue Next 3Y9.88%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
FLGT Yearly Revenue VS EstimatesFLGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
FLGT Yearly EPS VS EstimatesFLGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 45.17, which means the current valuation is very expensive for FLGT.
FLGT's Price/Earnings is on the same level as the industry average.
FLGT is valuated expensively when we compare the Price/Earnings ratio to 27.03, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for FLGT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 45.17
Fwd PE N/A
FLGT Price Earnings VS Forward Price EarningsFLGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FLGT Per share dataFLGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

A cheap valuation may be justified as FLGT's earnings are expected to decrease with -41.03% in the coming years.
PEG (NY)N/A
PEG (5Y)2.04
EPS Next 2Y-81.78%
EPS Next 3Y-41.03%

More info and screens

0

5. Dividend

5.1 Amount

FLGT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FULGENT GENETICS INC

NASDAQ:FLGT (8/5/2025, 8:16:46 PM)

After market: 20.78 0 (0%)

20.78

+2.42 (+13.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners54.65%
Inst Owner Change-0.75%
Ins Owners33.42%
Ins Owner Change7.81%
Market Cap632.54M
Analysts77.78
Price Target22.44 (7.99%)
Short Float %9.19%
Short Ratio7.42
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)129.32%
Min EPS beat(2)121.2%
Max EPS beat(2)137.43%
EPS beat(4)4
Avg EPS beat(4)172.16%
Min EPS beat(4)121.2%
Max EPS beat(4)298.21%
EPS beat(8)7
Avg EPS beat(8)139.31%
EPS beat(12)11
Avg EPS beat(12)145.2%
EPS beat(16)15
Avg EPS beat(16)113.81%
Revenue beat(2)2
Avg Revenue beat(2)3.16%
Min Revenue beat(2)1.07%
Max Revenue beat(2)5.24%
Revenue beat(4)2
Avg Revenue beat(4)0.65%
Min Revenue beat(4)-1.93%
Max Revenue beat(4)5.24%
Revenue beat(8)5
Avg Revenue beat(8)4.41%
Revenue beat(12)9
Avg Revenue beat(12)6.22%
Revenue beat(16)12
Avg Revenue beat(16)6.53%
PT rev (1m)0%
PT rev (3m)13.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.9%
EPS NY rev (1m)0%
EPS NY rev (3m)16.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.08%
Valuation
Industry RankSector Rank
PE 45.17
Fwd PE N/A
P/S 2.09
P/FCF N/A
P/OCF N/A
P/B 0.57
P/tB 0.66
EV/EBITDA N/A
EPS(TTM)0.46
EY2.21%
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-1.97
FCFYN/A
OCF(TTM)-0.82
OCFYN/A
SpS9.96
BVpS36.68
TBVpS31.65
PEG (NY)N/A
PEG (5Y)2.04
Profitability
Industry RankSector Rank
ROA -4.25%
ROE -4.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 40.04%
FCFM N/A
ROA(3y)-2.25%
ROA(5y)12.71%
ROE(3y)-2.41%
ROE(5y)14.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-21.53%
GM growth 5Y-7.75%
F-Score6
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 144.73%
Cap/Sales 11.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.01
Quick Ratio 6.01
Altman-Z 5.62
F-Score6
WACC8.86%
ROIC/WACCN/A
Cap/Depr(3y)101.39%
Cap/Depr(5y)338.11%
Cap/Sales(3y)8.31%
Cap/Sales(5y)7.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1433.33%
EPS 3Y-68.94%
EPS 5Y22.18%
EPS Q2Q%-53.33%
EPS Next Y-214.49%
EPS Next 2Y-81.78%
EPS Next 3Y-41.03%
EPS Next 5YN/A
Revenue 1Y (TTM)4.3%
Revenue growth 3Y-34.15%
Revenue growth 5Y54.21%
Sales Q2Q%15.17%
Revenue Next Year9.64%
Revenue Next 2Y10.04%
Revenue Next 3Y9.88%
Revenue Next 5YN/A
EBIT growth 1Y-1.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.56%
EBIT Next 3Y25.57%
EBIT Next 5YN/A
FCF growth 1Y-290.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-144.97%
OCF growth 3Y-66.06%
OCF growth 5Y30.8%